A Phase 2, Double-blind, Randomized, Placebo-controlled Study of Nelotanserin Versus Placebo in Subjects With Dementia with Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) Who Have REM Sleep Behavior Disorder (RBD)
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Nelotanserin (Primary)
- Indications Dementia; Lewy body disease; Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors Axovant Sciences
- 09 Nov 2017 According to an Axovant media release, top-line data expected in the second quarter of 2018.
- 05 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Mar 2018.
- 05 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2018.